Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration

Clinical Cancer Research

Volumn 2, Issue 2, 1996, Pages 311-317

  Lindner P ^a   Heath, D ^b   Howell, S ^b   Naredi, P ^a   Hafstrom L ^c  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE; FLUOROURACIL; LYPRESSIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; SWINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; ETOPOSIDE; FLUOROURACIL; INJECTIONS, INTRAPERITONEAL; LYMPH; PERITONEUM; SWINE; VASOPRESSINS;

EID: 0029867556     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Gyves, J. W , Ensminger, W. D. Stetson, P., Niederhuber, J. E., Meyer, M., Walker, S., Janis, M. A., and Gilbertson, S. Constant intraperitoneal 5-fluorouracil infusion through a totally implanted system. Clin. Pharmacol. & Ther., 35: 83-89, 1984.
2. Sugarbaker, P. H., Graves, T., DeBruijn, E. A., Cunliffe, W. J., Mullins, R. E., Hull, W. E., and Oliff, L. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. Cancer Res., 50: 5790-5794, 1990.
3. Speyer, J. L., Sugarbaker, P. H., Collins, J. M., Dedrick, R. L., and Klecker, R. W., Jr. Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res., 41: 1916-1922, 1981.
4. Markman, M. Intraperitoneal cisplatin chemotherapy in the management of ovarian carcinoma. Semin. Oncol., 16: 79-82, 1989.
5. Zimm, S., Cleary, S. M., Lucas, W. E., Weiss, R. J., Markman, M., Andrews, P. A., Schiefer, M. A., Kim, S., Horton, C., and Howell, S. B. Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide. Cancer Res., 47: 1712-1716, 1980.
6. Lindnér, P., Heath, D., Shalinsky, D. R., Howell, S., Naredi, P., and Hafstrom, L. Regional lymphatic drug exposure following intraperitoneal administration of 5-fluorouracil, carboplatin and etoposide. Surg. Oncol , 2: 105-112, 1993.
7. Dedrick, R. L., Myers, C. E., Bungay, P. M., and DeVitan V. T., Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat. Rep., 62: 1-11, 1978.
8. Welt, F. G. P., and Rutlen, D. L. Effect of vasopressin on systemic capacity. Am. J. Physiol., 261: H1494-H1498, 1991.
9. Elferink, F., Vander Vijgh, W. J F., Klein, I., ten Bokkel Huiink, W. W., Dubbleman, R., and McVie, J. G. Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother. Pharmacol., 21. 57-60, 1988.
10. Wung, W. E., and Howell, S. B. Simultaneous liquid-chromatography of 5-fluorouracil, uridine, hypoxanthine, xanthine, uric acid, allopurinol, and oxipurinol in plasma. Clin. Chem., 26: 1704-1708, 1980.
11. Markman, M., and Howell, S. B. Intraperitoneal chemotherapy: principles and results of clinical trials. In: F. M. Muggia (ed.). Concepts, Clinical Developments, and Therapeutic Advances in Cancer Chemotherapy, pp. 39-59. Boston: Martinus Nijhoff, 1987.
12. Yoffey, J. M., and Courtice, F. C. Lymphatics, Lymph and the Lymphomyeloid Complex. London: Academic Press, 1970.
13. Felt, J., Richard, C , McCaffrey, C., and Levy, M. Peritoneal clearance of creatinine and inulin during dialysis in dogs: effect of splanchnic vasodilators. Kidney Int., 16: 459-469, 1979.
14. Allen, L. M., and Creaven, P. J. Comparison of the human pharmacokinetics of VM-26 and VP-16, two anti-neoplastic epipodophyllotoxin glucopyranoside derivatives. Eur. J. Cancer, 11: 697-707, 1975.
15. Alberts, P. Y., Liu, E. V., Hannigan, R., O'Toole, S. D., Williams, J., Young, E. W., Franklin, D., Clarke-Pearson, V. K., Malvyia, B., DuBeshter, W., Hoskins, M., Adelson, R. D., Alvarez, S., Vogl, J., O'Sullivan, D. J., and Garcia, D. Phase III study of intraperitoneal (IP) cisplatin (CDDP)/intravenous (IV) cyclophosphamide (CPA) vs IV CDDP/IV CPA in patients (PTS) with optimal disease stage III ovarian cancer: a swog-gog-ecog intergroup study (INT 0051) (Abstract). ASCO, 14: 273, 1995.
16. Los, G., Verdegaal, E. M., and Mutsaers, P. H. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother. Pharmacol., 28: 159-165, 1991.
17. Sugarbaker, P. H., Zhu, B-W., Banez Sese, G., and Shmookler, B. Peritoneal carcinomatosis from appendiceal cancer: results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. Dis. Colon Rectum, 36: 323-329, 1993.